Willis Towers Watson Announces Changes with Respect to the Board of Directors
Appointment of Four New Directors Supported by
New Board-Level Committee to Help Oversee the Company’s Operational Transformation Plan
Three of the four new directors (
In addition, in connection with the transition to the new CEO and the addition of new Board members on
“We have been very pleased with the response of
“We welcome the appointment of
As previously announced,
The Board’s focus on director succession will continue during 2022, leading up to the 2022 annual meeting of shareholders. In order to reduce the size of the Board back to nine directors, two other current
The Company will continue to provide updates with respect to this transition, including the identity of directors who will be transitioning off the Board. “We are very excited about our strategic plan and the value that we think that it will deliver to
“We are very pleased to have
New Director Bios
About
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements and other forward-looking statements in this document by words such as “may”, “will”, “would”, “expect”, “anticipate”, “aim”, “believe”, “estimate”, “plan”, “intend”, “continue”, or similar words, expressions or the negative of such terms or other comparable terminology. These statements include, but are not limited to, statements regarding future leadership transitions, the company’s strategic plan and operational transformation plan, the company’s future results, plans, objectives, expectations and intentions and other statements that are not historical facts. Such statements are based upon the current beliefs and expectations of Willis Towers Watson’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements.
Factors that could cause actual results to differ from those set forth in the forward-looking statements are identified under “Risk Factors” and elsewhere in Willis Towers Watson’s most recent Annual Report on Form 10-K and in subsequent quarterly reports filed with the SEC.
You should not rely upon forward-looking statements as predictions of future events because these statements are based on assumptions that may not come true and are speculative by their nature. Willis Towers Watson does not undertake an obligation to update any of the forward-looking information included in this document, whether as a result of new information, future events, changed expectations or otherwise.
Media Contacts
Source:



Crawford & Company® and Aon Publish Joint Cyber Claims Guide
Everest Re Group Announces Dividend
Advisor News
- Addressing the ‘menopause tax:’ A guide for advisors with female clients
- Alternative investments in 401(k)s: What advisors must know
- The modern advisor: Merging income, insurance, and investments
- Financial shocks, caregiving gaps and inflation pressures persist
- Americans unprepared for increased longevity
More Advisor NewsAnnuity News
- Globe Life Inc. (NYSE: GL) Making Surprising Moves in Monday Session
- Aspida Life and WealthVest Offer a Powerful New Guaranteed Income Product with the WealthLock® Income Builder
- Lack of digital tools drives wedge between insurers, advisors
- LIMRA: Annuity sales notch 10th consecutive $100B+ quarter
- AIG to sell remaining shares in Corebridge Financial
More Annuity NewsHealth/Employee Benefits News
- We can't afford to let Democrats lead health care 'reform' | Opinion
- Expanding Medicaid coverage lowered death rates for young adults with kidney failure
- GLP-1s: Rewriting the relationship between pharmacy benefits and stop-loss
- Studies from Denise Wolff et al Have Provided New Data on Atopic Dermatitis (AMCP Market Insights: Beyond skin deep on the role of managed care in moderate to severe atopic dermatitis): Skin Diseases and Conditions – Atopic Dermatitis
- New Clinical Trials and Studies Findings from RAND Corporation Described (Benefit design and consumer information: results from a randomized trial): Clinical Research – Clinical Trials and Studies
More Health/Employee Benefits NewsLife Insurance News
- 3 ways AI can help close the gap for women’s insurance coverage
- Best’s Market Segment Report: AM Best Revises Outlook on Italy’s Life Insurance Segment to Stable From Negative
- Globe Life Inc. (NYSE: GL) Making Surprising Moves in Monday Session
- Dan Scholz to receive NAIFA’s Terry Headley Lifetime Defender Award
- Best’s Special Report: US Property/Casualty and Health Insurers Exceed Cost of Capital; Life Insurers Narrowly Miss
More Life Insurance News